Lixte Biotechnology (NASDAQ:LIXT) Announces Quarterly Earnings Results

Lixte Biotechnology (NASDAQ:LIXT) released its earnings results on Monday. The company reported ($0.29) earnings per share (EPS) for the quarter, Zacks reports.

Lixte Biotechnology Stock Performance

Shares of LIXT opened at $1.26 on Tuesday. Lixte Biotechnology has a fifty-two week low of $1.02 and a fifty-two week high of $3.50. The business has a 50-day moving average of $1.23 and a 200 day moving average of $1.72. The firm has a market cap of $3.95 million, a P/E ratio of -0.73 and a beta of 0.40.

Lixte Biotechnology Company Profile

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.